Assessing Efficacy

  • Tullio GiraldiEmail author


This chapter discusses the extensive use of a variety of quackery remedies in the nineteenth century, promoted by charlatans with the most extravagant promises. Their popularity and wide use posed, in addition to the problem of the assessment of the efficacy , the problem of the safety of these preparations. Indeed, these remedies sometimes contained toxic ingredients, and in some instances caused severe poisoning and death. To avoid these catastrophes, specific legislative measures were adopted after the First World War and regulatory agencies were established in the USA and later in other countries; after the Second World War , evidence of efficacy was also required for medicinal products. Evidence-based medicine thus provided safe and effective medicines, but did this happen to antidepressants ?


  1. Adams, C. P., & Brantner, V. V. (2006). Estimating the cost of new drug development: Is it really $802 Million? Health Affairs, 25(2), 420–429.CrossRefPubMedGoogle Scholar
  2. Altman, L. K. (1998). Who goes first. The story of self-experimentation in medicine. Berkley: University California Press.Google Scholar
  3. Angell, M. (2004). The truth about the drug companies. How they deceive us and what to do about it. New York: Random House.Google Scholar
  4. Baumeister, A. A., Hawkins, M. F., & Uzelac, S. M. (2003). The myth of the reserpine—induced depression: Role in the historical development of the monoamine hypothesis. Journal of the History of Neurosciences, 12(2), 207–220.CrossRefGoogle Scholar
  5. Bracken, M. B. (2013). Risk, chance and causation. Investigating the origins and treatment of diseases. New Haven, CT: Yale University Press.CrossRefGoogle Scholar
  6. Brody, T. (2012). Clinical trials. Study design, endpoints and biomarkers, drug safety, FDA and ICH guidelines. Amsterdam: Elsevier.Google Scholar
  7. Crofton, J. (2006). The MRC randomized trial of streptomycin and its legacy: A view from the clinical front line. Journal of Royal Society of Medicine, 99(10), 531–534.CrossRefGoogle Scholar
  8. Daniel, T. M. (2006). Historical review. The history of tuberculosis, in respiratory medicine, 100(11), 1862–1870.PubMedGoogle Scholar
  9. Davies, D. L., & Shepherd, M. (1955). Reserpine in the treatment of anxious and depressed patients. Lancet, 269(6881), 117–120.CrossRefPubMedGoogle Scholar
  10. deForest Lamb, R. (1936). American chamber of horrors: The truth about food and drugs. New York: Farrar & Rinehart.Google Scholar
  11. Emsley, J. (2005). The elements of murder. Oxford: Oxford University Press.Google Scholar
  12. Goozner, M. (2004). The $800 million pill. The truth behind the cost of new drugs. Oakland: University of California Press.Google Scholar
  13. Greenfield, J. (1974). Wilhelm reich vs. the U.S.A. New York: W.W. Norton & Company Inc.Google Scholar
  14. Griffenhagen, G. B., & Young, J. H. (1959). Old English patent medicines in America. Washington: Smithsonian Institution.Google Scholar
  15. Hager, T. (2006). The demon under the microscope. From battlefield hospitals to Nazi labs, one doctor’s heroic search for the world’s first miracle drug. New York: Harmony Books.Google Scholar
  16. Helm, K. A. (2007). Protecting public health from outside the physician’s office: A century of FDA regulation from drug safety labeling to off-label drug promotion. Fordham Intellectual Property, Media & Entertainment Law Journal. Retrieved May 30, 2016, from
  17. Jolliffe, D. M. (1993). A history of the use of arsenicals in man. Journal of the Royal Society of Medicine, 86(5), 287–289.PubMedPubMedCentralGoogle Scholar
  18. Kaptchuk, T. J. (1998). Powerful placebo: The dark side of the randomised controlled trial. Lancet, 351(9117), 1722–1725.CrossRefPubMedGoogle Scholar
  19. Krimsky, S. (2003). Science in the private interest. Has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefields Publishers Inc.Google Scholar
  20. Lind, J. (1753). Accessed 10 Mar 2014.
  21. Macklis, R. M. (1993). The great radium scandal. Scientific American, 269(2), 94–99.Google Scholar
  22. Macklis, R. M., Bellerive, M. R., & Humm, J. L. (1990). The radiotoxicology of radithor. Analysis of an early case of latrogenic poisoning by a radioactive patent medicine. The Journal of American Medical Association, 264(5), 619–621.CrossRefGoogle Scholar
  23. Medical Research Council Investigation. (1948). Streptomycin treatment of pulmonary tuberculosis. British Medical Journal, 2(4582), 769–782.CrossRefGoogle Scholar
  24. Nobel Prize in Physiology and Medicine. (1939). Accessed 13 Mar 2014.
  25. Nobel Prize in Physiology and Medicine. (1957). Accessed 14 Mar 2014.
  26. Nobel Prize in Physiology and Medicine. (2005). Accessed 13 Mar 2014.
  27. Preskorn, S. H. (2007). The evolution of antipsychotic drug therapy: Reserpine, chlorpromazine, and haloperidol. Journal of Psychiatric Practice, 13(4), 253–257.CrossRefPubMedGoogle Scholar
  28. Schou, M., Juel-Nielsen, N., Strömgren, E., et al. (1954). The treatment of manic psychoses by the administration of lithium salts. Journal of Neurology Neurosurgery and Psychiatry, 17(4), 250–260.CrossRefGoogle Scholar
  29. Shorter, E. (2011). A brief history of placebos and clinical trials in psychiatry. Canadian Journal of Psychiatry, 56(4), 193–197.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Singh, S., & Ernst, E. (2008). Trick or treatment; alternative medicine on trial. London: Bantam Press.Google Scholar
  31. Timmermans, S., & Berg, M. (2003). The gold standard: The challenge of evidence-based medicine and standardization in health care. Philadelphia: Temple University Press.Google Scholar
  32. Washburn, J. (2005). University, Inc. The corporate corruption of American higher education. New York: Basic Books.Google Scholar
  33. Wax, P. M. (1995). Elixirs, diluents, and the passage of the 1938 federal. Food, Drug and Cosmetic Act, in Annals of Internal Medicine, 122(6), 456–461.CrossRefPubMedGoogle Scholar
  34. WHO. (1995). World Health Organization. WHO technical report series, no. 850, 1995, Annex 3. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products.Google Scholar
  35. Young, J. H. (1990). The toadstool millionaires: A social history of patent medicines in America before federal regulation. In Quackwatch. Accessed 7 Mar 2014.

Copyright information

© The Author(s) 2017

Authors and Affiliations

  1. 1.University of TriesteTriesteItaly

Personalised recommendations